Tacrolimus Ointment Interest (PROTOPIC ®) in the Maintenance Treatment of Severe Seborrheic Dermatitis

Inclusion Criteria:

• in Phase 1: Attack Treatment (open)

1. over the age of eighteen patient,

2. Seborrheic dermatitis Severe,

3. participation with an informed consent,

4. Women of childbearing age in effective contraception for the duration of thestudy or postmenopausal women.

• in Phase 2: Phase 2: "Randomization" (blind)

1. Patient achieved a complete or almost complete clinical remission after theinitial treatment,

2. known immunodeficiency (HIV patient receiving chemotherapy) or immunosuppressivetherapy or biotherapy,

3. patient taking regular systemic corticosteroids at a dose> 20 mg / day

4. erythematous lesions with topography other than the face and evocative scalppsoriasis (elbows, knees ...), by referring to the possibility that the faciallesions correspond to lesions sebopsoriasis,

5. woman pregnant, nursing or in childbearing potential without effectivecontraception,

6. man wishing to have a child during the study period,

7. Ultra Violet (UV) phototherapy or usual realization of UV sessions aestheticpurposes,

8. Seborrheic dermatitis symptomatic of an underlying disease known or revealing

9. history of cancer or lymphoma,

10. progressive cancer or lymphoma,

11. Seborrheic dermatitis exclusively affecting the scalp,

12. known allergy to one-component products study ,

13. malnourished patient or sick history of chronic pancreatitis by a suspect todeficiency dermatitis,

14. participation in a clinical trial on the Seborrheic dermatitis in the previous 90days,

15. patient with lesions considered potentially malignant or pre-cancerous,

16. patient with abnormal skin barrier.

Exclusion Criteria:

• in Phase 1: Attack Treatment (open)

1. Patient had already been treated with Protopic ® for Seborrheic Dermatitis,

• Phase 2: "Randomization" (blind) 1) Patient with no complete or almost completeclinical remission after the initial treatment,